Member Info for Pingu777

Haha seems I’ve timed that impressively poorly there! Ha

See where go from here. Relaxed.

MMs dip to 10p and just under and the buys flood in. Cementing a really strong base at this level before next move up.

Bowie, do you have any friends?

It’s good to talk.

Hi Porky
Pharma obviously inherently risk with the chances of failure at each stage of pre clinical and clinical trials.

One of HEMOs USP bits of tech is their mice platform which allows the candidate drugs to be tested in mice with effectively human Immune systems for much longer than it’s rivals. A significant advancement in itself.

Compare a month and half as seems to be the average from my research compared to up to five months for the HEMO mice. Vlad is very very pleased with his move. If they are as good as he says then we are suggesting that we have strong testing results in a human immune system for five months which suggests safety phase one trials in humans should hopefully replicate pre-clinicals. This, for me, is a huge de-risking factor minimising the risk of failure at any point in phase one trials and phase two. Once we are past these timescales we are in unchartered territory but the nature of the treatment (Monoclonal antibodies) Bring with it a toxicity profile well understood to be very low.

So chance of failure within the next twelve months for me is v low (relative to the pharma world).

HEMO is a complete package not just the 2 candidates closest to clinical trials.

If we see the drugs work well as hoped and safely of course in human trial With pre clinical Trial results strongly replicated then the mice get strong validation.

Then the other projects were working on (SAFE HEMO CAR T... lupus etc) pre clinical results come with more credibility.

HEMO will snowball in value as the milestones are ticked off throughout the next few months and into 2021.

I don’t see the chance for people to hang on on the sidelines waiting for certain milestones soon as they have this year particularly for the CDX deal. The value will be seen and the SP will head significantly north.

Oh and I expect a Covid update soon.

Monoclonal antibodies can only be produced to a limited level each month for the proposed treatments. And they’re talking about a triple ****tail?!?! It’ll be so expensive and reduce the production capacity. How much would a Vlad perfected single monoclonal antibody Covid treatment be worth? People thinking the boat has sailed just need to wait and see what Vlad has for us when it is time.

You need to read all the RNSs from this year imo. You can skip the price monitoring extensions.

The Eli deal will generate some cash but essentially we’re a pre-clinical R&D play hitting clinical trials on two products in the next six months with one deal, if signed, landing imminently. And a next gen development platform which will be heavily validated as trials prove the drugs are effective and safe. We will be a significant take over target at this point.

Try RNSs from April 30 til the end of June which should give you a fair snapshot of the picture For HEMO... if for some reason you don’t have time to actually read every one of the RNSs for the company you’re putting your money into.

Afzal isn’t a 10% man. He’ll be holding for sure long term. Ask him on twitter.

Lunus chatting to a Director is pleasing to hear for me! Particularly the comments that it’s going well. Usually if things aren’t going well you get ‘no comment’. Exciting to hear he wants to speak on Friday. Does this indicate anything? Who knows

What an excellent update.

An area of cutting edge science lauded for its potential effectiveness but big players still tentative to dive due to safety concerns in implementing the treatment. HEMO just letting everyone know they look to have succeeded in managing the safety control of their already proven effective CAR T.

Dave (the market) and his mate, in shock at a HEMO RNS, stand stunned as something really big, fast and good flew over their heads.

"Anyone know what that was?" Said Dave's mate
"What you talking about? I just spilt brown sauce down my front. What have I missed?" replied Dave
"Everything Dave, as per usual"

Agree dhub. Time to sit back and be patient! Confidence and trust in Vald to get it done and in Sir Marcs positive words that HEMO is reaching its inflection point!

Agree. Theyll come when they are ready but they are on track with management expectations.

Covid is a double edged sword. It will have made the roll out of the VR/AR headsets maybe slightly more challenging but conversely it has brought swathes if interest and opportunity and the spot light has been on online Ed tech now more than ever.

Happy to hold and sit back and wait for things to develop.

If you sell based on scare mongering on this chat then you don’t want to be investing!

The company are progressing key projects and there is no material negative news around contracts, deals or overall progress. Covid won’t be helping things of course adding an extra challenge but all in all the updates are undoubtedly very very positive to me.

An operational update at some point when possible would be welcome. But there’s no indication of problems I can see. If someone is offloading some shares who has a fair few then who can knock taking a profit?!?! Market mechanics.

I’m no expert either! But I’ve read a lot so have peace of mind and see past swimming’s lame posts.

Swimming loves to undermine people’s confidence. He loves it. Strange behaviour to try and make investors think there are things wrong with the company he is invested in also thus encouraging sells and dipping his own holding value?

I personally saw zero problems from the RNS which to me limits the chance of failure. In terms of slippage on timescales... Vlad rarely commits to anything anyhow but I’m happy and aware that most things take a long time to execute in pharma. We are in the middle of a pandemic also which has slowed us down re:CDX in particular.

Reprobus I like your work. You’ve added more to the BB in one post than swimming has in two and had years. He’s been invested here for ages yet doesn’t trust the company and can’t understand how big pharma work.

Patience here people. Sir Marc Feldmann says we’re in track. I trust him also... more than I trust swimming anyway

Think about what work is involved in preparing for human trials. The drug must be prepared into its final state for production and manufacturing. Who does this? Us or Eli or someone else Eli work with? Which hospitals will be trial the drug at? Do the doctor and nurses need training on dosage? The supply of the drug needs managing - supplying multiple hospitals at some point to trial it with enough patients.

Plenty to do to conclude pre-clinical work and prepare for clinical. Clinical Trial plans go into the IND enabling application to prove the drug is ready to be taken forward so I believe this work is all being completed at this very moment.

I’m quite sure Eli know what they’re doing. Things take time. What else do you expect from Vlad? We will get RNSs at the right time when things are finalised in each area.

You either trust him or you don’t. I’m firmly in the Vlad camp and will be to see HEMO through its key milestones over the next year.

Two penne the

One, Hemo are efficient With their half year reports check the history of RNSs. V likely to come tomorrow.

Two, the report contains excellent levels of detail. All relevant project should/will be covered.

Three, very interested to see the details on COVID. I think we’ve been working on it heavily now for most of the year.

Four, financials are literally irrelevant to me. Except cash burn and income from mice. Although cash burn should be low and well managed and we’ve only cranked up spending since CAR T/PENN deal and the finance raise.

Five, I trust Vlad. The pandemic has knocked us back a bit particularly with the CDX deal delay as it busted up the human trial planning. But every single indication has been that of success with all projects and drugs.

Six, the deal for CDX closes in every day. It’s a biggy and will be worth waiting for.

Seven, HEMO is so much more de risked than beginning of the year. So however long it takes to to reach the transformational points of success, the chance of failure dwindles offering so much more security than literally every pre-clinical pharma out there. Primarily driven by the mice.

Good luck everyone. Can’t wait to read the update.

And for clarity feldmanns new associate company Focussed on cell regeneration after physical injury and has nothing to do with blood cancer and disease. NOT a rival and not a concern for HEMO investors.

A deramp cross ramp.

Can’t you just cross ramp? HEMO doing just fine fella. Pandemic not helped but big things are approaching...

They go to the same cult meetings!

Why have to run down HEMO to reference Sir Feldmanns new associated Company next year? I hope he does great things helping the company out like he does Hemo. And hopefully for you his new link spends millions on PR and somehow they do everything faster than all other slow coach junior pharmas. It’ll be a show in!

You do understand they are completely independent of each other as two separate companies? Seriously, I just don’t get you! Strange behaviour.

Stop replying to him and the other douche bags. They make the BB a farce.

News this week should give more clarity around numbers as per CEOs previous comments.

Patience.

Filtered pingu... for some reason.

It’s a blood bath out here!

Derampers a good sign, especially factless ones

Is that a good thing Gotham? Impersonating them?